Skip to main content
SpringerLink
Log in

ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma

  • Research Letter
  • Published:
World Journal of Pediatrics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Data availability

All data generated or analyzed during this study are included in this published article.

References

  1. Marc TG, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. National Cancer Institute Bethesda. MD: NIH Publications; 1999. p. 65–72.

    Google Scholar 

  2. Gurney JG, Smith MA, Ross JA. Cancer among infants. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. National Cancer Institute Bethesda. MD: NIH Pub; 1999. p. 149–56.

    Google Scholar 

  3. Aravindan N, Jain D, Somasundaram DB, Herman TS, Aravindan S. Cancer stem cells in neuroblastoma therapy resistance. Cancer Drug Resist. 2019;2:948–67.

    PubMed  PubMed Central  Google Scholar 

  4. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203–16.

    Article  CAS  PubMed  Google Scholar 

  5. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O’Leary M, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28:2625–34.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Santana VM, Furman WL, McGregor LM, Billups CA. Disease control intervals in high-risk neuroblastoma. Cancer. 2008;112:2796–801.

    Article  PubMed  Google Scholar 

  7. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer. 2011;56:578–83.

    Article  PubMed  Google Scholar 

  8. Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy. J Pediatr Hematol Oncol. 2013;35:337–47.

    Article  CAS  PubMed  Google Scholar 

  9. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol. 2009;27:1007–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Cole KA, Maris JM. New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clin Cancer Res. 2012;18:2423–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D. Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol. 2004;26:227–32.

    Article  PubMed  Google Scholar 

  12. Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, Conte M, et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer. 2009;45:2835–42.

    Article  PubMed  Google Scholar 

  13. London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011;29:3286–92.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma Lancet. 2007;369:2106–20.

    Article  CAS  PubMed  Google Scholar 

  15. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224:1121–4.

    Article  CAS  PubMed  Google Scholar 

  16. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313:1111–6.

    Article  CAS  PubMed  Google Scholar 

  17. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc sequences in primary human neuroblastomas: correlation with advanced disease stage. Prog Clin Biol Res. 1985;175:105–13.

    CAS  PubMed  Google Scholar 

  18. Valentijn LJ, Koster J, Haneveld F, Aissa RA, van Sluis P, Broekmans ME, et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci U S A. 2012;109:19190–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Suganuma R, Wang LL, Sano H, Naranjo A, London WB, Seeger RC, et al. Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children’s Oncology Group and the International Neuroblastoma Pathology Committee. Pediatr Blood Cancer. 2013;60:363–70.

    Article  PubMed  Google Scholar 

  20. Carén H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J. 2008;416:153–9.

    Article  PubMed  Google Scholar 

  21. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008;455:971–4.

    Article  CAS  PubMed  Google Scholar 

  22. George RE, Sanda T, Hanna M, Fröhling S, Luther W 2nd, Zhang J, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455:975–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930–5.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Duijkers FAM, Gaal J, Meijerink JPP, Admiraal P, Pieters R, de Krijger RR, et al. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome. Am J Pathol. 2012;180:1223–31.

    Article  CAS  PubMed  Google Scholar 

  25. Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 2009;69:7338–46.

    Article  CAS  PubMed  Google Scholar 

  26. Htike W, Islam MA, Hasan MT, Ferdous S, Rifat M. Factors associated with treatment delay among tuberculosis patients referred from a tertiary hospital in Dhaka City: a cross-sectional study. Public Health Action. 2013;3:317–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kramer M, Ribeiro D, Arsenian-Henriksson M, Deller T, Rohrer H. Proliferation and survival of embryonic sympathetic neuroblasts by MYCN and activated ALK signaling. J Neurosci. 2016;36:10425–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Schönherr C, Ruuth K, Kamaraj S, Wang CL, Yang HL, Combaret V, et al. Anaplastic lymphoma kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene. 2012;31:5193–200.

    Article  PubMed  Google Scholar 

  29. Somasundaram DB, Subramanian K, Aravindan S, Yu Z, Natarajan M, Herman T, et al. De novo regulation of RD3 synthesis in residual neuroblastoma cells after intensive multi-modal clinical therapy harmonizes disease evolution. Sci Rep. 2019;9:11766.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Aravindan N, Somasundaram DB, Herman TS, Aravindan S. Significance of hematopoietic surface antigen CD34 in neuroblastoma prognosis and the genetic landscape of CD34-expressing neuroblastoma CSCs. Cell Biol Toxicol. 2021;37:461–78.

    Article  CAS  PubMed  Google Scholar 

  31. Cheng Y, Chen X, Ye L, Zhang Y, Liang J, Liu W, et al. The prognostic significance of NEK2 in hepatocellular carcinoma: evidence from a meta-analysis and retrospective cohort study. Cell Physiol Biochem. 2018;51:2746–59.

    Article  CAS  PubMed  Google Scholar 

  32. Liang Q, Ma D, Gao RF, Yu KD. Effect of Ki-67 expression levels and histological grade on breast cancer early relapse in patients with different immunohistochemical-based subtypes. Sci Rep. 2020;10:7648.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Schulte JH, Bachmann HS, Brockmeyer B, Depreter K, Oberthur A, Ackermann S, et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res. 2011;17:5082–92.

    Article  CAS  PubMed  Google Scholar 

  34. Lamant L, Pulford K, Bischof D, Morris SW, Mason DY, Delsol G, et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol. 2000;156:1711–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Dirks WG, Fahnrich S, Lis Y, Becker E, MacLeod RA, Drexler HG. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int J Cancer. 2002;100:49–56.

    Article  CAS  PubMed  Google Scholar 

  36. Lee JW, Park SH, Kang HJ, Park KD, Shin HY, Ahn HS. ALK protein expression is related to neuroblastoma aggressiveness but is not independent prognostic factor. Cancer Res Treat. 2018;50:495–505.

    Article  CAS  PubMed  Google Scholar 

  37. Chen S, Zhou C, Ma X, Gong L. Abnormality of anaplastic lymphoma kinase gene and its expression in pediatric neuroblastoma. Zhonghua Bing Li Xue Za Zhi. 2014;43:541–5 (in Chinese).

    CAS  PubMed  Google Scholar 

  38. Wang M, Zhou C, Sun Q, Cai R, Li Y, Wang D, et al. ALK amplification and protein expression predict inferior prognosis in neuroblastomas. Exp Mol Pathol. 2013;95:124–30.

    Article  CAS  PubMed  Google Scholar 

  39. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008;455:967–70.

    Article  CAS  PubMed  Google Scholar 

  40. Lee CC, Jia Y, Li N, Sun X, Ng K, Ambing E, et al. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J. 2010;430:425–37.

    Article  CAS  PubMed  Google Scholar 

  41. Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014;26:682–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Devoto M, Specchia C, Laudenslager M, Longo L, Hakonarson H, Maris J, et al. Genome-wide linkage analysis to identify genetic modifiers of ALK mutation penetrance in familial neuroblastoma. Hum Hered. 2011;71:135–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, et al. The ALKF1174L mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell. 2012;22:117–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Zhu S, Lee JS, Guo F, Shin J, Perez-Atayde AR, Kutok JL, et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell. 2012;21:362–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13:397–411.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Kumps C, Fieuw A, Mestdagh P, Menten B, Lefever S, Pattyn F, et al. Focal DNA copy number changes in neuroblastoma target MYCN regulated genes. PLoS One. 2013;8:e52321.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Bellini A, Bernard V, Leroy Q, Rio Frio T, Pierron G, Combaret V, et al. Deep sequencing reveals occurrence of subclonal ALK mutations in neuroblastoma at diagnosis. Clin Cancer Res. 2015;21:4913–21.

    Article  CAS  PubMed  Google Scholar 

  48. Chang HH, Lu MY, Yang YL, Chou SW, Lin DT, Lin KH, et al. The prognostic roles of and correlation between ALK and MYCN protein expression in neuroblastoma. J Clin Pathol. 2020;73:154–61.

    Article  CAS  PubMed  Google Scholar 

  49. Fredlund E, Ringnér M, Maris JM, Påhlman S. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci U S A. 2008;105:14094–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Hasan MK, Nafady A, Takatori A, Kishida S, Ohira M, Suenaga Y, et al. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma. Sci Rep. 2013;3:3450.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Pilling AB, Kim J, Estrada-Bernal A, Zhou Q, Le AT, Singleton KR, et al. ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget. 2018;9:8823–35.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the Stephenson Cancer Center (SCC) Cancer Tissue pathology core and the SCC Cancer Functional Genomics core for all the TMA, IHC, and scanning services. The authors also acknowledge the OUHSC Staff Editor (Ms. Kathy Kyler) for the help in critically reviewing this manuscript.

Funding

This work was partially or in full funded by the Oklahoma Center for the Advancement of Science and Technology (No. OCAST-HR19-045), National Institutes of Health (No. NIH-P20GM103639), and NIH-NCI Cancer Center Support Grant (No. P30CA225520).

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, BMSB 311C, Radiation Biology Laboratory, University of Oklahoma Health Sciences Center, 940 Stanton L. Young Boulevard, Oklahoma City, OK, 73104, USA

    Dinesh Babu Somasundaram & Natarajan Aravindan

  2. Stephenson Cancer Center, Oklahoma City, OK, USA

    Sheeja Aravindan & Natarajan Aravindan

  3. Plainsboro, NJ, USA

    Nandita Gupta

  4. Department of Pathology, BMSB 311C, Radiation Biology Laboratory, University of Oklahoma Health Sciences Center, 940 Stanton L. Young Boulevard, Oklahoma City, OK, 73104, USA

    Zhongxin Yu & Natarajan Aravindan

  5. Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

    Ashley Baker

Authors
  1. Dinesh Babu Somasundaram
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheeja Aravindan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nandita Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhongxin Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ashley Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Natarajan Aravindan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SDB contributed to performing experiments, acquisition of the data, data analysis and interpretation. AS contributed to performing experiments, acquisition of the data, data analysis and interpretation, and helped in critically revising the manuscript. GN contributed to the acquisition of in silico data from R2 portal. YZ and BA contributed to biospecimen and clinical data collection, histopathological grading, and data interpretation. AN contributed to the conception and design of the experiments, performing experiments, data acquisition, analysis and interpretation, and drafted the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Natarajan Aravindan.

Ethics declarations

Ethical approval

All protocols were approved by the Institutional Review Board (IRB) University of Oklahoma Health Sciences Center, with permission for the research use of de-identified specimens.

Conflict of interest

All authors have no conflict of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (XLSX 14 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Somasundaram, D.B., Aravindan, S., Gupta, N. et al. ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma. World J Pediatr 18, 285–293 (2022). https://doi.org/10.1007/s12519-022-00517-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12519-022-00517-5

Search

Navigation